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Dynamic regulation of insulin signaling and meta-
bolic gene expression is critical to nutrient homeo-
stasis; dysregulation of these pathways is widely
implicated in insulin resistance and other disease
states. Though the metabolic effects of insulin are
well established, the components linking insulin
signal transduction to a metabolic response are not
as well understood. Here, we show that Cdc2-like
kinase 2 (Clk2) is an insulin-regulated suppressor of
hepatic gluconeogenesis and glucose output. Clk2
protein levels and kinase activity are induced as
part of the hepatic refeeding response by the
insulin/Akt pathway. Clk2 directly phosphorylates
the SR domain on PGC-1a, resulting in repression
of gluconeogenic gene expression and hepatic
glucose output. In addition, Clk2 is downregulated
in db/db mice, and reintroduction of Clk2 largely
corrects glycemia. Thus, we have identified a role
for and regulation of the Clk2 kinase as a component
of hepatic insulin signaling and glucose metabolism.
INTRODUCTION
Hepatic gluconeogenesis, the net production of glucose from
substrate molecules, is critical for adaptation to fasting condi-
tions and contributes to hyperglycemia in diabetes (Biddinger
and Kahn, 2006; Pilkis and Granner, 1992; Quinn and Yeagley,
2005). In the fed state, insulin normalizes blood glucose levels
by increasing glucose uptake in peripheral tissues and by sup-
pressing gluconeogenesis in the liver. Though the metabolic
effects of insulin have been studied for decades, a mechanistic
understanding of insulin signal transduction is just recently
coming into focus. In the liver, most of insulin’s metabolic effects
are through activation of insulin receptor PI3K and Akt pathways.
Akt can directly suppress hepatic gluconeogenesis by negatively
regulating the gluconeogenic transcriptional regulators: Foxo1,
PGC-1a, and CRTC2 (also known as TORC2) (Dentin et al.,
2007; Li et al., 2007; Matsumoto et al., 2007; Nakae et al., 2001;
Puigserver et al., 2003).
The PGC-1a transcriptional coactivator is an important
mediator of hepatic fasting metabolism; PGC-1a induces andCmaintains expression of the gluconeogenic gene program during
fasted states, responding to glucagon/cAMP through CRTC2
(Herzig et al., 2001; Koo et al., 2005; Rhee et al., 2003; Yoon
et al., 2001). During the fed state, insulin/Akt can suppress
PGC-1a activity through several mechanisms. Akt can directly
phosphorylate S570 in PGC-1a’s serine-arginine (SR) domain
(Li et al., 2007). In addition, the PGC-1a SR domain interacts
with Foxo1 in an insulin/Akt-dependent manner (Puigserver
et al., 2003). These studies suggest that the PGC-1a SR domain
acts as an insulin-responsive domain to control its gluconeo-
genic function.
The Cdc2-like kinases (Clk), also termed LAMMER kinases,
are an evolutionary conserved family of dual-specificity CMGC
kinases found in most, if not all, eukaryotes. They are putative
high-level regulators of alternative splicing through phosphoryla-
tion of SR domains on splicing factors (Colwill et al., 1996b; Dun-
can et al., 1995; Hanes et al., 1994; Hillman et al., 2004; Lee et al.,
1996; Prasad et al., 1999). However, there is an extremely limited
understanding of Clk targets, function, and regulation in a biolog-
ical context. Here, we show that a member of the Clk kinases,
Clk2, is regulated by feeding/fasting cycles in the liver. In the
refed state, hepatic Clk2 is induced by insulin/Akt signaling,
during which Clk2 then phosphorylates the SR domain on
PGC-1a. Clk2 phosphorylation of PGC-1a causes potent repres-
sion of gluconeogenic gene expression and hepatic glucose
output that leads to hypoglycemia.RESULTS
Feeding and Insulin/Akt Regulate Clk2
We and others have previously found that the SR domain is an
insulin-responsive region of PGC-1a (Li et al., 2007; Puigserver
et al., 2003). In splicing factors, hyperphosphorylation of SR
regions can modulate their function and activity (Prasad et al.,
1999). In order to investigate the signaling and transcriptional
metabolic effects of the feeding/insulin response, we hypothe-
sized that the Clk kinases responsible for SR domain phosphor-
ylation of splicing factors may be involved in PGC-1a feeding/
insulin regulation. Among the Clk kinases tested, we identified
Clk2 as being regulated by nutritional status. Clk2 protein
had low abundance in mouse liver extracts following 24 hr of
fasting; however, Clk2 protein was strongly induced after 4 hr
of refeeding and remained elevated at longer refeeding time
points (Figure 1A). Clk2 protein levels were also regulated in
gastrocnemius muscle and in the heart by fasting/feeding, albeitell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc. 23
Figure 1. Clk2 Is Regulated by Feeding/Fasting and Insulin
(A) Clk2 protein is induced in the mouse liver by refeeding. Western blot analysis of liver whole-cell extracts from mice sacrificed at indicated time during a feeding-
fasting-refeeding time course.
(B) Clk2 mRNA levels are not regulated by fasting/feeding in the mouse liver. Q-RT-PCR analysis of Clk2, Pepck, and PGC-1a gene expression from total liver
RNA isolated from mice in (A). Data are presented as average ± SEM; n = 2–3.
(C) Clk2 protein is induced by insulin downstream of PI3K and Akt. Whole-cell extracts from FAO hepatoma cells were grown in RPMI + 0.5% BSA for 24 hr and
treated with indicated inhibitor overnight prior to insulin stimulation for 1 hr.
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tion of many classic feeding/fasting genes, which occurs at
the transcriptional level, steady-state Clk2 mRNA levels were
largely unchanged (Figure 1B). Of note, induction of Clk2 pro-
tein correlated with suppression of Pepck and PGC-1a gene
expression.
Because elevation of serum insulin during refeeding is a major
stimulator of the hepatic refed metabolism, we tested whether
insulin was sufficient to regulate Clk2 protein levels. Treatment
of FAO rat hepatoma cells with insulin strongly induced Clk2
protein (Figure 1C). The insulin induction of Clk2 was blocked
by treatment with the PI3K inhibitor LY294002 and the Akt 1/2
inhibitor Akt VIII, suggesting that the PI3K/Akt pathway mediated
the effects of insulin on Clk2 protein. In addition, intraperitoneal
injection of insulin into fasted mice similarly induced Clk2 protein
(data not shown). Together, these results suggest that hepatic
Clk2 protein levels are regulated by insulin during feeding/fasting
nutrient cycles.24 Cell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc.Insulin, Akt, and Clk2 Kinase Activity Control Clk2
Protein Stability
Based on the fact that Clk2 protein levels were strongly regulated
by feeding and insulin, we next investigated the mechanisms
responsible by which Clk2 protein levels fluctuate during nutrient
cycles. Of interest, in addition to the PI3K/Akt dependence of
Clk2 induction, treatment with TG003, a Clk2 inhibitor (Muraki
et al., 2004), also blocked the insulin induction of Clk2
(Figure 1C). This suggested that Clk2 protein levels may be regu-
lated by Clk2 kinase activity. Indeed, ectopic expression of
a wild-type Clk2 construct (Clk2 WT) resulted in a highly ex-
pressed, stable protein. In contrast, a kinase-dead ATP-binding
mutant of Clk2 (K192R) (Nayler et al., 1998) was very unstable
(Figures 2A and 2B). To further confirm that Clk2 kinase activity
regulated protein levels, we decided to test whether the stability
of the K192R mutant could be rescued by coexpression with WT
Clk2. Figure 2A shows that titrating increasing amounts of
HA-Clk2 WT could completely rescue the stability of Flag-Clk2
Figure 2. Clk2 Kinase Activity Controls Clk2 Protein Stability
(A) WT Clk2 rescues stability of kinase-dead mutant. HEK293 cells were transfected with a constant amount of indicated Flag-tagged Clk2 construct with
increasing amounts of indicated HA-Clk2 construct. All transfection amounts were normalized with empty vector plasmid.
(B) TG003 induces Clk2 degradation. Western blot analysis of HEK293 cells transfected with indicated Clk2 construct overnight prior to a 1 hr treatment with 0, 10,
20, or 40 mM TG003.
(C) TG003 degradation of Clk2 is dependent on residues S98 and Y99. Western blot analysis of HEK293 cells transfected with indicated Clk2 constructs and
treated with 40 mM TG003 1 hr prior to harvest.
(D) Clk2 ubiquitination. Western blot analysis of whole-cell extracts (input) or following Flag immunoprecipitation (IP:Flag) of H2.35 hepatocytes transfected with
indicated Clk2 construct and 8 3 HA-ubiquitin. Cells were serum starved overnight prior to treatment with 10 mM MG132 ± 100 nM insulin for 2 hr.
(E) Alignment of Clk activation loops. Amino acid residues shaded in gray indicate conservation to Mus musculus Clk2; red residue indicates T343. Residues
underlined on Mus Clk1 were found to be phosphorylated in crystal structure of human Clk1 (PDB: 2VAG).
(F) Phosphorylation at S342/T343 is induced upon insulin stimulation in H2.35 hepatocytes transfected with Flag-Clk2 and serum starved prior to treatment with
indicated inhibitor for 30 min prior to stimulation with insulin for 1 hr.
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that Clk2 protein levels may be regulated by Clk2 kinase
activity. Moreover, treatment with Clk inhibitor TG003 strongly
decreased the stability of WT-Clk2 and did not further decreaseCthe stability of the K192R kinase-dead mutant (Figure 2B). Stabi-
lization of K192R by WT Clk2 was also blocked by TG003 treat-
ment (Figure S1B). By performing deletion mapping (data not
shown), we found that the effects of TG003 on Clk2 stabilityell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc. 25
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region renders Clk2 protein resistant to TG003-dependent
degradation (Figure 2B) without altering Clk2 kinase activity
(data not shown). Further refinement of this region showed that
amino acids S98/Y99 were required for TG003-dependent Clk2
degradation (Figure 2C). These results suggest that fluctuations
of Clk2 protein levels during feeding/fasting cycles may be regu-
lated by Clk2 kinase activity itself.
The regulation of Clk2 protein stability suggested that ubiqui-
tination and proteasomal degradation might be involved. Indeed,
coexpression of Flag-Clk2 with HA-tagged ubiquitin resulted in
low levels of ubiquitination on WT Clk2 (Figure 2D). In contrast,
the less-stable K192R mutant displayed high levels of
ubiquitination, and the S98A/Y99A mutant (which is more stable
in the presence of TG003) showed no detectable ubiquitination
(Figures 2D and S1C). Of interest, S98 and Y99 are highly
conserved sites on vertebrate Clk2s (Figure S1D); however,
this region is specific to Clk2 and shows no conservation or
homology to any region on mammalian Clk paralogs. We have
also identified S98/Y99 as residues that are autocatalytically
phosphorylated (Figures S1E and S1F), suggesting that S98/
Y99 is a conserved functional region on Clk2, potentially a degron
sequence that controls Clk2 stability.
The data presented above clearly demonstrate how Clk2
protein levels could be controlled by Clk2 kinase activity. More-
over, these results hint that Clk2 kinase activity could be
responding to insulin signaling to control Clk2 protein levels.
Consistent with this idea, treatment of H2.35 hepatocytes with
insulin or expression of myristoylated Akt decreased ubiquitina-
tion of WT Clk2 (Figures 2D and S1C). However, neither insulin
nor myristolated Akt had an effect on ubiquitination of Clk2
catalytic mutants K192R and T343A. In addition, ubiquitination
of endogenous Clk2 was similarly regulated in primary hepato-
cytes (Figure S1G). These data suggested that insulin/Akt could
stabilize Clk2 protein by a similar mechanism through which Clk2
regulates its own stability. However, insulin and myristolated
Akt could not rescue the stability of a kinase-dead Clk2 (Figures
2D, S1C, and S1H), suggesting that Clk2 kinase activity is
required for the complete insulin/Akt stabilization of Clk2.
Activation loop phosphorylation is a common mechanism
regulating enzymatic activity of kinases (Nolen et al., 2004). In
fact, mapping of Clk2 phosphorylation sites identified a phos-
phopeptide that corresponded to the activation loop of Clk2
(Figure S1E), but the exact phosphorylated residue was ambig-
uous. Of interest, in the deposited Protein Data Bank crystal
structure of the Human Clk1 catalytic domain (PDB:2VAG), the
activation loop was dually phosphorylated on residues that
correspond to S342 and T343 on mouse Clk2 (Pike et al.,
2007) (Figure 2E). Clk activation loops are very highly conserved
throughout evolution (Figure 2E), suggesting that phosphoryla-
tion may be a conserved point of regulation (Farkas et al.,
2009). In order to test whether any residues on Clk2’s activation
loop had a functional role in activity, we constructed point muta-
tions of all phosphorylatable activation loop residues, and only
T343 affected Clk2 activity (Figures S2A and S2B). Stability of
the T343A mutant protein resembled that of the K192R (Figures
2D, S1C, and S2C), and an in vitro assay showed that the kinase
activity of the T343A mutant was 20% of that of WT Clk2
(Figure S2D), whereas the S342A mutation did not have an effect26 Cell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc.on kinase activity or stability (Figures S2C and S2D). Moreover,
in vitro, both Clk2 and Akt phosphorylated the Clk2 catalytic
domain (Figure S2E), and Akt2 could specifically phosphorylate
the T343 residue (Figure S2F). We used an antibody directed
toward phospho-S342/T343 Clk2 to demonstrate that this site
is regulated by insulin in hepatocytes (Figure 2F). In addition,
Akt and Clk2 physically interact, as demonstrated by coimmuno-
precipitation experiments with ectopically expressed and
endogenous proteins (Figures S2G and S2H), and in vitro, Akt
specifically interacted with the Clk2 kinase domain (Figure S2I).
Together, these results suggest that T343 phosphorylation (by
Akt and/or Clk2 itself) on the Clk2 activation loop is an important
regulatory mechanism controlling Clk2 kinase activity and
stability in response to insulin and feeding.
Clk2 Phosphorylates and Represses PGC-1a
The fact that Clk kinases phosphorylate SR regions (Bullock
et al., 2009; Colwill et al., 1996b; Duncan et al., 1998; Prasad
et al., 1999; Prasad and Manley, 2003) and PGC-1a contains
an insulin-responsive SR domain and is counter regulated
to Clk2 by fasting/feeding in the liver prompted us to test
whether Clk2 could directly phosphorylate PGC-1a SR domain.
Clk2 robustly phosphorylated full-length GST-PGC-1a in vitro
(Figure 3A), and mapping experiments showed that Clk2 exclu-
sively phosphorylated the SR domain on PGC-1a (Figure S3A).
In addition, overexpression of Clk2 was sufficient to phosphory-
late PGC-1a on the SR domain as demonstrated by phospho-
Akt-substrate antibodies and by a shift in PGC-1a mobility
(Figure 3B). Importantly, insulin treatment resulted in increased
PGC-1a SR domain phosphorylation, which was largely blocked
by Clk2 shRNA (Figures 3C and S3B). In primary hepatocytes,
Clk2 expression led to high levels of PGC-1a phosphorylation
that were not further augmented by insulin treatment (Fig-
ure S3B). In vitro analysis showed that Clk2 phosphorylates
the PGC-1a SR domain and catalyzes autophosphorylation
with similar efficacy (Figure S3C). Together, these results indi-
cate that Clk2 kinase mediates the insulin-responsive phosphor-
ylation of the PGC-1a SR domain.
To investigate the functional consequence of Clk2 phosphor-
ylation on PGC-1a, we performed luciferase-based transcrip-
tional reporter assays. PGC-1a strongly activates the HNF4a
gAF-1 response element (Puigserver et al., 2003; Rhee et al.,
2003); however, coexpression of WT Clk2, but not kinase-dead
mutants, repressed PGC-1a activity in a dose-dependent
manner (Figures 3D, S2A, and S2B). Clk2 inhibition was reversed
by treatment with the Clk2 inhibitor TG003 (Figure 3D). Clk2
could also repress PGC-1a activation of Foxo1 on the IRS
response element (Figure S3D), as well as repress the Pepck
promoter (Figure S3E). Of interest, Clk2 did not repress the
PGC-1a transcriptional activation of the NRF-1 transcription
factor (Figure S3F), suggesting that Clk2 repression of PGC-1a
may be transcription factor specific.
Because Clk2 strongly and exclusively phosphorylated the SR
domain on PGC-1a, we determined whether this region was
required for Clk2 repression of PGC-1a. A PGC-1a allele lacking
the SR domain (DSR) had transcriptional activity comparable
to full-length protein; however, DSR is resistant to Clk2 repres-
sion (Figure 3E). The entire SR domain of PGC-1a was involved
in Clk2-mediated repression, as PGC-1a constructs lacking
Figure 3. Clk2 Phosphorylates and Re-
presses PGC-1a Transcriptional Coacti-
vator
(A) Domain map and in vitro phosphorylation
of PGC-1a with indicated deletion by purified
recombinant Clk2 kinase (rClk2) in the presence
of g32P-ATP reaction conditions described in
Experimental Procedures.
(B) Clk2 induces PGC-1aSR domain phosphoryla-
tion recognized by P-Akt substrate antibodies.
Western blot analysis of Flag immunoprecipitates
from primary hepatocytes infected with indicated
adenoviruses. All viral loads were normalized
with Ad-GFP.
(C) Clk2 shRNA blocks insulin induction of PGC-1a
phosphorylation. Western blot analysis of Flag
immunoprecipitates (IP:Flag) and whole-cell
extracts of H2.35 hepatocytes infected with indi-
cated adenoviruses. Cells were serum starved
overnight prior to insulin stimulation as indicated.
PGC-1a transcription coactivation assay in (D)
HEK293 cells and (E) H2.35 hepatocytes using
HNF-4a and gAF1-luiferase reporter performed
as described in Experimental Procedures.
(F) Q-RT-PCR analysis of G6Pase expression in
total RNA from primary hepatocytes infected
with indicated adenoviruses. Data is presented
as average ± SEM. Significance was determined
by unpaired two-tailed Student’s t test. **p < 0.01.
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Clk2 (Figures 3E and S3G). Large-scale analysis involving muta-
tion of the phosphorylatable residues (S, T, and Y) in the SR
domain to alanine showed that such mutations rendered PGC-
1a similarly resistant to Clk2 repression (Figures S3H and S3I).
We next tested whether Clk2 repression of PGC-1a had an
effect on endogenous gluconeogenic target genes. As expected,
adenovirus-mediated expression of PGC-1a strongly induced
the gluconeogenic gene G6Pase in primary hepatocytes (Fig-
ure 3F). Coinfection of Clk2 adenovirus with PGC-1a, but not
the PGC-1a DSR allele, potently repressed this induction
(Figure 3F). Moreover, Clk2 shRNAs (Figure S4A) further induced
PGC-1a-dependent G6Pase and Pepck gene expression in
primary hepatocytes (Figure 4A). These results indicate thatCell Metabolism 11, 23–Clk2 kinase is a repressor of PGC-1a
transcriptional activity on gluconeogenic




To gain a clearer understanding of how
Clk2 functions in the context of feeding/
fasting hormonal regulation of hepatic
glucose metabolism, we performed Clk2
gain-of-function experiments. Treatment
of primary hepatocytes with forskolin
and dexamethasone (Fsk + Dex) mimics
the fasting action of glucagon and glu-
cocorticoids, respectively, by strongly
inducing the gluconeogenic gene pro-gram: Pepck, G6Pase, and PGC-1a (Quinn and Yeagley,
2005). Whereas expression of Clk2 only had modest effects in
unstimulated/serum starved primary hepatocytes, it almost
completely blunted the Fsk + Dex induction of gluconeogenic
genes (Figure 4B). Importantly, Clk2 kinase activity was required
to repress gluconeogenic genes, as expression of Clk2 K192R
did not have a large effect (Figure 4B). We did, however, observe
that K192R stabilizes endogenous PGC-1a protein in primary
hepatocytes (Figure S4B). Similar results with Clk2 and K192R
were observed with overexpressed PGC-1a (which mimics
many of the effects of Fsk + Dex on gene expression) in primary
hepatocytes (Figures S4C and S4D). Overall Clk2 acts as
a general suppressor of PGC-1a activity in primary hepatocytes,
suppressing PGC-1a induction of genes involved in many34, January 6, 2010 ª2010 Elsevier Inc. 27
Figure 4. Clk2 Represses Gluconeogenic
Gene Expression in Primary Hepatocytes
(A) Clk2 shRNA induces gluconeogenic gene
expression. Q-RT-PCR analysis of total RNA
from primary hepatocytes infected with GFP or
PGC-1a and control shRNA or Clk2 shRNA adeno-
viruses. Cells were grown for 2 days postinfection
in DMEM + 10% FBS; n = 4.
(B) Clk2 expression suppresses gluconeogenic
gene expression. Q-RT-PCR analysis of total
RNA from primary hepatocytes infected with
GFP, Clk2, or Clk2 K192R adenoviruses. At 24 hr
after infection, cells were switched to starvation
media 6 hr prior to treatment with 10 mM forskolin
and 1 mM dexamethasome for 1.5 hr; n = 4. All data
are presented as average ± SEM. Experiments
were performed at least three times with similar
results. Significance was determined by two-tailed
unpaired Student’s t test. *p < 0.05; **p < 0.01.
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However, Clk2’s most potent effects by far are on regulation of
gluconeogenic gene expression (Figure S4E).
These studies were broadened in vivo, where modest adeno-
viral-mediated Clk2 expression in the liver (3- to 4-fold over
endogenous-fed Clk2 protein levels) (Figure S5A) resulted in
significant fasting hypoglycemia (Figure 5A). Clk2 also strongly
repressed hepatic glucose output, as measured by an intraperi-
toneal pyruvate tolerance test (Figure 5B), which correlated with
reduced gluconeogenic gene expression of Pepck, G6Pase, and
PGC-1a (Figure 5C). Clk2 expression also resulted in lower levels
of endogenous PGC-1a protein, which migrated with an upward
shift in an SDS PAGE (Figure S5B), similar to the shift in PGC-1a
caused by Clk2 expression in primary hepatocytes (Figures 4D
and S3B). These in vivo effects of Clk2 are largely dependent
on PGC-1a; coinfection of PGC-1a shRNA and Clk2 was not
additive, nor were they synergistic, suggesting that the effects
of Clk2 on hepatic gluconeogenic gene expression require
PGC-1a (Figure 5D). Next, we used Clk2 shRNA adenovirus to
test the in vivo requirement for Clk2 in the refeeding repression
of gluconeogenesis. Mice infected with Clk2 shRNA have
impaired refeeding suppression of gluconeogenic gene expres-
sion, which is most significant after 4 and 9 hr of refeeding
(Figure 5E). Taken together, these results indicate that Clk2 is
a potent repressor of hepatic gluconeogenesis. Moreover, as
Clk2 is induced by insulin/Akt in the refed state, these data
suggest that Clk2 may be an important component of the phys-
iologic refed response by suppressing gluconeogenesis.28 Cell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc.Clk2 Expression Normalizes db/db
Diabetic Phenotype
Elevation of hepatic glucose output in
type II diabetic patients, as well as in
animal models of obesity and diabetes
due to insulin resistance, is well docu-
mented (Biddinger and Kahn, 2006;
Quinn and Yeagley, 2005). Because Clk2
is a suppressor of PGC-1a on gluconeo-
genic gene expression and hepatic glu-
cose production, we hypothesized thatdysregulation of Clk2 could potentially be an underlying mecha-
nism of increased hepatic glucose output in a diabetic state. We
decided to test this hypothesis using the leptin-resistant db/db
mouse model. As expected, in the fed state, db/+ heterozygous
control mice (Leprdb/+) showed high levels of Clk2 protein in
the liver; however, the diabetic and obese db/db mice (Leprdb/
Leprdb) showed a striking downregulation of hepatic Clk2
protein (Figure 6A). Upon a 12 hr fast, Clk2 protein was downre-
gulated in both control and db/db mice, though still at lower
levels in the db/db mice. This led us to ask whether we could
rescue hyperglycemia in db/dbmice by reintroduction of hepatic
Clk2. Consistent with the effects observed in Balb/c mice
(Figure 5), hepatic Clk2 expression in db/db mice dramatically
reduced glucose production from pyruvate to a level similar to
control db/+ mice (Figure 6B), which correlated with reduced
fasting gluconeogenic gene expression (Figure 6C) and lower
levels of PGC-1a protein (which also displayed a shift in mobility)
(Figure S5C). Of interest and similar to endogenous Clk2
(Figure 6A), we observed that expressed Clk2 was also at lower
levels in db/db mice compared to controls (Figure S5D), despite
elevated Clk2 mRNA (Figure S5E). This suggested to us that
the lower levels of Clk2 observed in db/db mice may be due to
dysregulation of Clk2 protein stability. Indeed, immunoprecipi-
tated Clk2 from db/db mice displays a much higher degree of
steady-state ubiquitination than does Clk2 from db/+ mice
(Figure S5F). Taken together, these data show that Clk2 is down-
regulated in the leptin-resistant db/db diabetic mouse, and
this correlates with elevated gluconeogenic activity. Moreover,
Figure 5. Clk2 Represses Hepatic Glucose Output and Causes Hypoglycemia In Vivo
(A) Hepatic Clk2 expression causes fasting hypoglycemia. Glycemia from mice infected with GFP, Clk2, or Clk2 K192R adenoviruses following a 9 hr fast.
n = 6–9.
(B) Clk2 suppresses hepatic glucose production in a pyruvate tolerance test. Intraperitoneal (IP) pyruvate tolerance test from mice infected with GFP (N = 4)
or Clk2 (N = 5) adenoviruses. Mice fasted overnight prior to injection of 2 g/kg sodium pyruvate. Data are presented as change in glycemia following pyru-
vate injection.
(C) Clk2 suppresses hepatic gluconeogenic gene expression in vivo. Q-RT-PCR analysis of gluconeogenic gene expression from total liver RNA from mice
infected with GFP (n = 5), Clk2 (n = 6), or Clk2 K192R (n = 3) adenoviruses following a 9 hr fast.
(D) Clk2 suppression of gluconeogenesis requires PGC-1a. Q-RT-PCR analysis of gene expression from mice infected with indicated adenovirus, fasted
overnight prior to sacrifice; n = 4.
(E) Hepatic Clk2 knockdown impairs refeeding suppression of gluconeogenic gene expression. Q-RT-PCR analysis of gene expression is presented as
percent of fasting expression. Data presented are average of multiple experiments for each virus and feeding condition. Fasted, n = 12; 2 hr refed, n = 4;
4 hr refed, n = 12; 9 hr refed, n = 4; 24 hr refed, n = 7. All data are presented as average ± SEM. Significance was determined by two-tailed unpaired
Student’s t test. *p < 0.05; **p < 0.01.
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Figure 6. Hepatic Clk2 Expression Normalizes db/db Diabetic
Phenotype
(A) Clk2 protein is downregulated in db/db mice. Western blot analysis of liver
whole-cell extracts from heterozygous control mice (Leprdb/+) or homozygous
db/db mice (Leprdb/Leprdb) sacrificed during the feeding or 12 hr fasted.
(B) Pyruvate tolerance test from db/db or db/+ mice infected with GFP or Clk2
adenovirus. Mice were fasted overnight prior to intraperitoneal administration
of 2 g/Kg pyruvate. Data are presented as average ± SEM. db/db mice, n = 4;
db/+ mice, n = 2. Significance indicated is determined between db/db GFP
versus db/db Clk2.
(C) Q-RT-PCR analysis of gluconeogenic gene expression from total liver RNA
from db/+ or db/db mice following an overnight fast. Data are presented as
average ± SEM. db/db mice, n = 4; db/+ mice, n = 2.
(D) Proposed model depicted regulation of Clk2 kinase activity, stability, and
suppression of PGC-1a and gluconeogenesis. Significance is determined by
two-tailed unpaired Student’s t test. *p < 0.05; **p < 0.01.
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30 Cell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc.reintroduction of Clk2 in the livers of db/db mice dramatically
restores the glucose phenotype to near control levels.
DISCUSSION
Insulin is a crucial component of glucose homeostasis by its
action in many tissues, the liver perhaps being the most central.
One of the key metabolic actions of insulin is repression of
hepatic gluconeogenesis. In this regard, we have identified the
Clk2 protein kinase as an insulin-regulated suppressor of hepatic
gluconeogenesis. In response to insulin signaling through PI3K/
Akt, Clk2 kinase activity is induced by phosphorylation of
the activation loop residue T343. Once Clk2 kinase activity is
induced, it undergoes autophosphorylation, which enhances
Clk2 protein stability. Clk2 can then phosphorylate the SR
domain on PGC-1a, causing repression of PGC-1a transcrip-
tional activity on gluconeogenic genes and reducing hepatic
glucose output (model outlined in Figure 6C).
Regulation of Clk2 by Nutritional Status and Insulin
The Clk family of kinases shows a very high degree of evolu-
tionary conservation, with most if not all eukaryotes having at
least one Clk kinase. Despite the prevalence of Clks, very little
is known about their activity, regulation, and function. Here, we
present detailed mechanistic insights into the regulation and
biological function of a mammalian Clk. Clk2 is subject to at
least two levels of regulation: by an initial stimulating phosphor-
ylation on the activation loop and by Clk2 kinase activity itself.
In response to insulin, Akt phosphorylates the activation loop
of the inactive and unstable Clk2 protein. Phosphorylation
of the activation loop induces Clk2 kinase activity, which is
required for Clk2 stability. Once induced and stable, Clk2 can
sustain activity and possibly amplify the initial signal by auto-
phosphorylation of its activation loop without the continual
need for Akt or another kinase/signal. Indeed, earlier work on
the Clks has shown that they are strongly autocatalytic and
has suggested that this is a crucial aspect of Clk activity (Duncan
et al., 1997; Lee et al., 1996; Nayler et al., 1998; Prasad and
Manley, 2003); however, that work has lacked a detailed mech-
anism of regulation.
PGC-1a SR Domain Phosphorylation
Early descriptions of Clks refer to their substrate specificity for
regions rich in SR domains (Colwill et al., 1996a, 1996b; Lee
et al., 1996; Nikolakaki et al., 2002). The SR domain on PGC-
1a is a well-documented regulatory region and has been shown
to mediate PGC-1a’s insulin responsiveness via interaction with
Foxo1 transcription factor and also contain an Akt phosphoryla-
tion site (Li et al., 2007; Puigserver et al., 2003). Taking this into
account, the identification of Clk2 as an insulin-dependent
PGC-1a SR domain kinase further confirmed the regulatory
function of the SR region. However, the mechanistic basis of
how the SR domain regulates PGC-1a activity remains elusive.
We have observed that the SR domain’s most potent regulatory
effects are on PGC-1a’s coactivation of nuclear receptors and
Foxo1 and do not appear to be a general repression of PGC-
1a on all transcription factors. Many nuclear proteins that contain
SR domains are known to interact with other proteins via these
domains. In fact, phosphorylation of SR domains has been
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Ngo et al., 2005), and it is possible that phosphorylation of
PGC-1a’s SR domain affects interaction with specific transcrip-
tional components, depending on transcription factors and
target promoters.
Another interesting aspect of this work is the implications on
alternative splicing. The Clks are putative regulators of alterna-
tive splicing through phosphorylation of SR domains (Stojdl
and Bell, 1999). Of note, the Clk2s are known to regulate the
alternative splicing of their own transcripts (Duncan et al.,
1997). Indeed, we have observed that alternative splicing of
Clk2 mRNA is highly regulated in a manner consistent with the
regulation presented here (J.T.R. and P.P., unpublished data).
In addition, PGC-1a has been implicated in splicing via its SR
and RNA recognition (RMM) domains (Knutti and Kralli, 2001;
Monsalve et al., 2000). Although the precise role of PGC-1a in
alternative splicing has not yet been documented, one inter-
esting hypothesis is that SR phosphorylation by Clk2 could
regulate binding of specific RNAs on PGC-1a’s SR and RRM
domains. We are currently exploring the possibility of PGC-1a
and Clk2 cooperation in regulated alternative splicing events.
Akt and Clk2 in Refed Hepatic Glucose Metabolism
Insulin suppression of hepatic gluconeogenesis is largely
dependent on the PI3K and Akt kinase pathways. Recent
work has shown that Akt can directly impinge on gluconeogen-
esis by negative regulation of the CRTC2, Foxo1, and PGC-1a
transcriptional regulators (Dentin et al., 2007; Li et al., 2007;
Nakae et al., 2001; Puigserver et al., 2003). Our identification
of Clk2 as an insulin-regulated kinase that suppresses gluco-
neogenesis may, at first, suggest a redundant function with
that of Akt. However, we believe that our data imply a separate
and potentially quantitative role of Clk2 and Akt in repression of
gluconeogenesis in the fed state. It is well established that Akt
activity is induced very rapidly following insulin stimulation,
during which it acutely suppresses the activity of CRTC2,
Foxo1, and PGC-1a. However, it is known that hepatic gluco-
neogenesis continues well into the later stages of refeeding
(Radziuk and Pye, 2001), suggesting that the suppressive
effects of insulin on gluconeogenesis are not immediate and
that gluconeogenesis requires several hours to be quantitatively
suppressed. We propose that Clk2 acts in a second and
perhaps more powerful phase of refeeding repression of gluco-
neogenesis. Thus, following initial insulin-stimulated phosphor-
ylation by Akt, Clk2 protein levels take several hours to build
up and achieve full induction, which strongly correlates with
the increasing suppression of Pepck gene expression during
refeeding. Consistent with this, in vivo knockdown of Clk2
impairs refeeding suppression of gluconeogenesis, particularly
at later stages (>4 hr) when Clk2 levels are elevated, but knock-
down has no effect on the initial suppression of gluconeogen-
esis (Figures 1A and 5E), which is most likely due to immediate
activation of Akt pathways. Of interest, we observe decreased
levels of Akt phosphorylation and phosphorylation of Akt targets
at these later stages of refeeding. This suggests to us that,
whereas Akt activity is downregulated after prolonged refeed-
ing, gluconeogenic targets display continued and increased
suppression (Figures 1A and 1B). Clearly, Akt cannot be the
only suppressive signal at these stages of refeeding, and weChypothesize that Clk2 is a major gluconeogenic suppressor at
these later stages. It is also interesting to note that glycolysis
and lipogenesis, other hallmarks of hepatic feeding metabolism,
are not immediately induced upon refeeding but take several
hours to achieve maximal expression (Horton et al., 2002;
Kalaany and Mangelsdorf, 2006; Postic et al., 2007), a pattern
of expression mirroring that of Clk2 induction. Although insulin
is widely considered the major stimulus of glycolytic and lipo-
genic pathways, the expression pattern upon refeeding sug-
gests that Akt is not a direct activator (Semple et al., 2009)
and that the role of Clk2, if any, in these pathways is an active
area of research.
Clk2 Regulation and Implications for Metabolic
Diseases
Our findings that Clk2 is downregulated in the livers of db/db
mice supply a disease context that further supports our model
of Clk2 being a suppressor of hepatic gluconeogenesis. The
db/db mice display elevated hepatic glucose output and hyper-
glycemia, and PGC-1a and CRTC2 are both elevated in db/db
livers (Dentin et al., 2007; Yoon et al., 2001). Notably, knockdown
of PGC-1a in livers of db/db mice is sufficient to significantly
reduce blood glucose levels (Koo et al., 2004), suggesting that
hyperactivity of hepatic PGC-1a is a major defect in this
insulin-resistant model. Our results suggest that activation of
Clk2 in a hyperglycemic and insulin-resistant state would reduce
hepatic glucose output and improve systemic glucose levels.
Though we present data showing that insulin strongly stabi-
lizes Clk2, it is presently unclear how Clk2 is negatively regu-
lated. Considering the nature of Clk2 autoregulation, there may
be a negative regulatory pathway that opposes Clk2 during
fasting and in diabetic models. Consistent with this, we observe
lower expression of endogenous as well as ectopic Clk2 in the
db/db diabetic mice, which also display elevated levels of ubiq-
uitination. This may suggest that hyperactivity of the ubiquitin
pathway/ligase responsible for Clk2 degradation is causal. We
have also shown that Clk2 ubiquitination can be regulated by
insulin, and an alternative explanation is that the insulin resis-
tance itself is enough to dysregulate Clk2 protein stability.
Currently, the identification of factors and pathways that control
Clk2 degradation is under investigation and might provide
important therapeutic targets to treat metabolic diseases.
EXPERIMENTAL PROCEDURES
Animals Procedures
All mouse experiments (except as noted) were performed with 6- to 10-week-
old male Balb/c mice purchased from Taconic. Male 7- to 9-week-old B6.Cg
Leprdb/Leprdb and heterozygous control mice were purchased from Jackson
Laboratory. Adenovirus infections were performed by tail vein injection of
0.5 3 109 infectious particles per mouse. Double infections were performed
using a total of 1.0 3 109 virus particles; all infection amounts were corrected
using GFP adenovirus. Glycemia was measured by tail bleeds using an Ascen-
cia Elite (Bayer). Pyruvate tolerance tests were performed by fasting animals
prior to intraperitoneal injection of 2 g/kg sodium pyruvate dissolved in PBS.
Animals that were fed a standard diet (22.5% protein, 11.8% fat, 52% carbo-
hydrate by mass) were sacrificed 5–7 days after infection by CO2 asphyxiation;
the livers were removed and snap frozen on liquid nitrogen until processing. All
animal experiments were performed in at least two independent trials with
similar results. All animal work was performed in accordance with Dana-Farber
Cancer Institute animal care and use policies.ell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc. 31
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Mouse primary hepatocytes were isolated using liver digest media (Invitrogen)
detailed protocol available upon request. Adenovirus infections were per-
formed using 1.0 3 107 infectious particles per well of a 6-well plate for
2.5 hr in maintenance media (DMEM 0.2% BSA, 1 nM insulin, 2% Na-pyruvate,
Pen/Strep). Cells were grown in starvation media (DMEM 0.2% BSA, 2%
Na-pyruvate, Pen/Strep) for 6 hr prior to insulin/fsk/dex treatments. Cells
were harvested 1–2 days after infection as indicated.
FAO hepatoma cells were cultured in F-12 media 5% FBS, Pen/Step.
Adenovirus infections were performed using 1.0 3 108 infectious particles
per well of a 6-well plate for 3 hr.
H2.35 SV-40-immortalized hepatocytes were cultured in DMEM 5% FBS,
5 mM glucose, 0.2 mM Dex, Pen/Strep. Adenovirus infections were performed
using 1.03 108 infectious particles per well of a 6-well plate for 4 hr. Transfec-
tions were performed with Lipofectamine LTX (Invitrogen) according to manu-
facturer’s recommendations.
HEK293 cells were cultured in DMEM 10% CCS, Pen/Strep. Transfections
were performed with Polyfect (QIAGEN) according to manufacturer’s recom-
mendations.
We obtained Bovine Insulin (I0516), Forskolin (F3917), and Dexamethasome
(D4902) from Sigma. LY294002 was obtained from Caymen Chemical;
MG132, from Andwin Scientific; U0126, from BIOMOL; and Akt VIII, TG003,
and Lactocystin, from CalBiochem.
Transcriptional Reporter Assays
HEK293 or H2.35 cells were grown and transfected as described above. All
transfection amounts were corrected with empty vector plasmid DNA. Cells
were grown for 24 hr posttransfection, harvested using 13 Reporter Lysis
Buffer (Promega). Luciferase counts were measured using Luciferase Sub-
strate (BD PharMingen) on a Fluorostar Optima (BMG). All experiments were
performed in at least two independent trials in duplicate-triplicate.
Recombinant Kinase Assays
Recombinant Akt2 kinase (Cell Signaling) experiments were carried out
according to manufacturer’s recommendations in Akt Kinase Buffer with
0.2 mM ATP. Recombinant Clk2 was made by cloning the Clk2 cDNA into
pGex 5x-2 and expressed in BL-21 bacteria (Promega) followed by IPTG
induction and purification using glutathione agarose (Roche). As indicated,
g32P-ATP was added at a 1:100 (hot:cold) molar ratio. Detailed purification
and kinase assay protocols are available upon request.
Constructs
Clk2 cDNA was cloned from mouse liver cDNA into pcDNA 3.1 (Invitrogen)
Flag- or HA-tagged expression vectors. All adenoviruses were constructed
using the pAd-Track/pAd-Easy system. Flag-Clk2 and Flag-Clk2 K192R
cDNAs are expressed by a CMV promoter. shRNA adenoviruses are
expressed by a U6 promoter: shControl (ccttcgattccctcaaagaca), shClk2#2
(ccttcgatttcctcaaagaca), shClk2#3 (gagaacagcagttaccgaa), and shClk2#4
(cggatgatcagaaagacaa). PGC-1a shRNA adenovirus was utilized as previously
described (Koo et al., 2004). All adenoviruses were purified by CsCl ultracen-
trifugation and titered by serial dilution/infection and quantifying GFP-express-
ing cells.
RT-PCR
Total RNA was isolated from cells or pulverized liver using Trizol (Invitrogen).
For Q-RT-PCR analysis, cDNA was synthesized using random primers and
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene
expression analysis was performed using a BioRad IQ5 and HotStart-IT
SYBER mix (USB). All gene expression data were corrected to 36B4 expres-
sion and normalized using DDCT method. All gene expression experiments
were performed in at least two independent experiments, each performed in
duplicate or triplicate. All primer sequences are available upon request.
Cell Extracts
Whole-cell extracts were prepared using RIPA buffer with 1 mM PMSF, 1 3
Protease Inhibitors (Roche), 30 mM glycerol 2-phosphate, 50 mM NaF, and
2 mM Na orthovanadate. Liver whole-cell extracts were prepared using a32 Cell Metabolism 11, 23–34, January 6, 2010 ª2010 Elsevier Inc.TissueLyzer (QIAGEN) in RIPA buffer. Liver nuclear extracts were prepared
as described (Rodgers and Puigserver, 2007).
Immunoprecipitations
Flag immunoprecipitations were performed using anti-Flag-M2-Agarose
(Sigma) in RIPA buffer. Akt/Clk2/Ubiquitin coimmunoprecipitations were per-
formed by harvesting the cells in 1% Triton X-100, 20 mM Tris-Cl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM Na-pyrophosphate, 1 mM
glycerol 2-phosphate, 1 mM Na-orthovandate, 1 mM PMSF, and 13 protease
inhibitors (Roche). Immunoprecipitations were performed with indicated anti-
body with anti-IgG agarose (True Blot, eBiosciences), protein A/G agarose
(Roche), anti-flag-agarose (Sigma), anti-HA-agarose (Sigma) for 3 hr at 4C;
immunoprecipitates were washed at least three times with lysis buffer and
resolved by SDS-PAGE.
Antibodies
Rabbit anti-Clk2 was a gift from Axel Ullrich. Rabbit anti-TORC2 (CRTC2) was
a gift from Marc Montminy. Rabbit anti-Phospho-S570 PGC-1awas a gift from
Morris Birnbaum. Anti-Clk2 and anti-phospho S342/T343A were from Cell
Signaling. We obtained M2-Flag-HRP (Sigma), HA-HRP (Roche), P-S256
Foxo1 and Tubulin (Upstate), Actin (Abchem), and PGC-1a (H300 Santa
Cruz and 4C1.3 Calbiochem). Akt, P-T308 Akt, P-S473 Akt, P-T24 Foxo1,
Foxo1, P-S21/9 GSK3, P-S133 CREB, P-Akt Substrate, and ubiquitin anti-
bodies were from Cell Signaling.
Mass Spectrometry
Protein from Coomassie-stained gel bands was in-gel reduced with DTT,
cysteine residues were alkylated with iodoacetamide, and the protein was
digested using either trypisn or chymotrypsin (Shevchenko et al., 1996). The
generated peptide mixtures were subjected to microcapillary liquid chroma-
tography tandem mass spectrometry on an LTQ Orbitrap (Thermo Fisher
Scientific) essentially as described elsewhere (Haas et al., 2006). MS/MS
spectra were assigned by searching them against the GST-Clk2 protein
sequence using the SEQUEST algorithm and allowing Ser, Thr, and Tyr resi-
dues to be phosphorylated (Eng et al., 1994). The precursor ion tolerance
for the search was set to ± 2 Da, and no enzyme specificity constraints
were applied. Peptide assignments were filtered to be consistent with the
enzyme specificity of the protease use for the digest and to have a mass
deviation of less than 7 ppm. Additional filtering through SEQUEST scores
XCorr and dCn was followed by manual validation of phosphopeptide MS/
MS spectra.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.cmet.2009.11.006.
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